Mr. Nicholson will discuss Chroma's business strategy and to provide updates on the progress of the company's lead agent, tosedostat, which is being progressed towards a global registration study in relapsed/refractory acute myeloid leukemia, along with its innovative portfolio of first-in-class clinical and preclinical agents utilising its novel macrophage-targeting (ESM) technology.
Enquiries
Chroma Therapeutics Limited Ian Nicholson Chief Executive Officer +44 (0)1235 829120 Richard Bungay Chief Financial Officer
Brunswick Jon Coles +44 (0)20 7404 5959 Justine McIlroy
About Chroma Therapeutics
Chroma Therapeutics, based in Oxford (UK), is a drug discovery and development company focused in the fields of oncology and inflammatory disorders. Chroma is building a broad pipeline of first- or best-in-class treatments utilising its expertise in chromatin biology and its novel intracellular accumulation technologies, which include the ability to selectively target drugs to macrophages. Chroma is backed by a number of leading specialist investors, including Abingworth, Essex Woodlands, Gilde, Phase4 and The Wellcome Trust. More information about Chroma can be found at www.chromatherapeutics.com.
Valerie Mugridge Executive Assistant
Brunswick Group LLP, 16 Lincoln's Inn Fields, London, WC2A 3ED, United Kingdom Tel +44 (0) 20 7404 5959 Direct +44 (0) 20 7396 5325 www.brunswickgroup.com
- Brunswick is a leading international corporate relations and communications consultancy
- Over 80 Partners worldwide across 16 offices in 11 countries
